Mirum Pharmaceuticals, Inc. 8K

Mirum Pharmaceuticals reported strong Q2 2026 revenue growth and raised full-year sales guidance while advancing multiple late-stage rare disease programs and refinancing its convertible debt, despite recording a substantial net loss and ending the quarter with negative stockholders’ equity.

On August 5, 2026, Mirum Pharmaceuticals, Inc. reported its second quarter 2026 financial results and raised full-year 2026 net product sales guidance to $680–$700 million on the back of $176.2 million in Q2 net product sales, while also providing a broad business update including new U.S. FDA Breakthrough Therapy and Orphan Drug Designations for volixibat in primary sclerosing cholangitis, completion of enrollment in the VANTAGE Phase 2b study in primary biliary cholangitis, progress across late-stage programs for brelovitug and LIVMARLI, an NDA under Priority Review for zilurgisertib with a September 26, 2026 PDUFA date, and significant capital structure actions involving the issuance of $690 million of 0.00% convertible senior notes due 2032 and the settlement of $237.2 million of 4.00% convertible senior notes due 2029, resulting in a larger cash balance but a net loss for the quarter and a stockholders’ deficit position as of June 30, 2026.

Filing Facts

CIK

1759425

Ticker

MIRM

Form

8K

Source Type

fda

Accession

0001759425-26-000044

Alert Tier

7